Close Menu

NEW YORK – While the COVID-19 pandemic has led Roche, and other diagnostic companies, to zero in on a virus and disease few knew about this time last year, the demand for other diseases hasn't let up.  

On a conference call on Thursday to discuss third quarter financial results, Roche leadership addressed the company's continuing portfolio of SARS-CoV-2 tests but emphasized other molecular tests are still being developed and rolled out as usual.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.